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ABSTRACT Hepatitis A virus, an hepatotropic picorna-
virus, is a common cause of acute hepatitis in man for which
there is no available vaccine. Competitive binding studies
carried out in solid phase suggest that neutralizing monoclonal
antibodies to hepatitis A virus recognize a limited number of
epitopes on the capsid surface, although the polypeptide
locations of these epitopes are not well defined. Neutralization-
escape mutants, selected for resistance to monoclonal antibod-
ies, demonstrate broad cross-resistance to other monoclonal
antibodies. Sequencing of virion RNA from several of these
mutants demonstrated that replacement of aspartic acid resi-
due 70 of capsid protein VP3 (residue 3070) with histidine or
alanine confers resistance to neutralization by monoclonal
antibody K2-4F2 and prevents binding of this antibody and
other antibodies with similar solid-phase competition profiles.
These results indicate that residue 3070 contributes to an
immunodominant antigenic site. Mutation at residue 102 of
VP1 (residue 1102) confers partial resistance against antibody
B5-B3 and several other antibodies but does not prevent
antibody attachment. Both VP3 and VP1 sites align closely in
the linear peptide sequences with sites of neutralization-escape
mutations in poliovirus and human rhinovirus, suggesting
conservation of structure among these diverse picornaviruses.
However, because partial neutralization resistance to several
monoclonal antibodies (2D2, 3E1, and B5-B3) was associated
with mutation at either residue 3070 or residue 1102, these sites
appear more closely related functionally in hepatitis A virus
than in these other picornaviruses.
Hepatitis A virus (HAV), a human picornavirus with tropism
for the liver, is responsible for both endemic and epidemic
hepatitis worldwide (1). Despite efforts to develop both
inactivated and attenuated vaccines, a practical HAV vac-
cine has yet to be produced for use in human populations.
Although the virus may be propagated in vitro in a variety of
primate cell lines (2-4), the yields of virus are generally low
and no clear cut markers of viral attenuation have yet been
identified. Similarly, attempts to express viral antigen from
recombinant cDNA have not resulted in immunogenic pro-
teins capable of eliciting neutralizing antibody (5, 6), reflect-
ing in part the highly conformational nature of the relevant
antigenic sites (7). Despite these difficulties, there is evidence
that the antigenic activity of the virus is comprised of
relatively few epitopes binding neutralizing antibody (8). We
have attempted to identify the molecular structures that
contribute to these immunogenic neutralization epitopes. As
the corresponding epitopes are well characterized for two
distantly related human picornaviruses with known three-di-
mensional structures, poliovirus type 1 (PV1) (9) and human
rhinovirus type 14 (HRV14) (10), identification of HAV
neutralization epitopes is also of interest from a comparative
viewpoint.
Virus mutants resistant to monoclonal antibody-mediated
neutralization have proven helpful in identifying immuno-
genic sites on these other picornaviruses (9-11), but the
application of this approach to characterization of HAV
antigenic sites has been hampered by the slow and inefficient
replication of HAV in vitro. Most HAV isolates are noncy-
topathic, are highly cell-associated, and demonstrate a sub-
stantial nonneutralizable fraction in vitro (4, 12). To over-
come these problems, a radioimmunofocus assay for HAV,
based on the immune autoradiographic detection of virus
replication foci developing beneath agarose overlays, has been
used to clonally isolate HAV-neutralization-escape mutants
resistant to a panel of neutralizing monoclonal antibodies (8,
13). In this report, we describe the further characterization of
these monoclonal antibodies and their related neutralization-
escape mutants.
METHODS
Monoclonal Antibodies to HAV. Monoclonal antibodies to
HAV were obtained from five laboratories (14, 15) (see Table
1). Each was tested for its ability to neutralize the HM175
strain of HAV in a radioimmunofocus-inhibition assay (16)
and to compete with other radioiodinated monoclonal anti-
bodies (K3-4C8 or B5-B3) for binding to virus as described
(8).
Selection of HAV-Neutralization-Escape Mutants. Sponta-
neous neutralization-escape mutants were selected from cell-
culture-adapted HM175 virus stock by repeated cycles of
neutralization that were followed by amplification in the
presence of neutralizing monoclonal antibodies, as described
(8). Mutant virus was clonally isolated from radioimmuno-
focus assay agarose overlays (17) and assessed for neutral-
ization resistance in a logarithmic reduction radioimmuno-
focus-inhibition assay (8, 16).
Amplification and Purification of HAV Mutants. Virus was
propagated in 850-cm2 roller bottle cultures of BS-C-1 cells in
the absence of antibody and purified from cell lysates by
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Table 1. Neutralizing monoclonal antibodies to HAV
Virus
Antibody strain Isotype Neut. index Source
Group A
K2-4F2 HM790 IgG2a 1.43 ± 0.31 A. MacGregor*
K3-4C8 IgG2a 1.22 ± 0.29
K3-2F2 IgG2a ND
Group B
B5-B3 KMW-1 IgG2a 0.90 ± 0.12 R. Teddert
Group C
6A5 CR326 IgG2a 1.62 ± 0.11 J. Hughest
1B9 IgG2a 1.22 ± 0.53 E. Eminit
2D2 IgG2a 2.00 ± 0.20 R. Geretyt
3E1 IgG2a 1.25 ± 0.12
Group D
10.09 CF53 IgG1 2.43 ± 1.14 D. Crevat§
813 IgG3 1.13 ± 0.44 E. Deloince§
Group E
AG3 S84-1 IgG1 0.69 C. Lill
AD2 IgG1 0.95
AE8 IgM 1.81
Neutralizing index = log1o reduction in titer ofHM175 virus (mean
± SEM). Neut., neutralizing; ND, not determined.
*Commonwealth Serum Institute, Melbourne, Australia.
tMiddlesex Hospital, London.
tMerck Institute for Therapeutic Research, West Point, PA.
§Clonatec, Paris.
IlSichuan Health and Anti-Epidemic Station, Chengdu City, P.R.C.
centrifugation through combination sucrose/cesium chloride
gradients (18).
Antibody Binding to HAV Mutants. A standardized quan-
tity of gradient-purified virus, measured by quantitative
cDNA-RNA hybridization, was applied to the wells of a
polyclonal antibody-coated polyvinylchloride microtiter
plate (19, 20). After extensive washing, '25I-labeled mono-
clonal antibody (K2-4F2, K3-4C8, or B5-B3) was added to
each well (direct assay). Alternatively, after incubation with
excess unlabeled monoclonal antibodies and subsequent
washing, radioiodinated goat anti-mouse immunoglobulin
(Kirkegaard and Perry Laboratories, Gaithersburg, MD) was
added to each well (indirect assay). After further washing
steps, the quantity of 1251 bound to mutant virus was
comphred with that bound to comparable amounts of the
parent HM175 virus.
RNA Sequencing. Gradient-purified virus was treated with
NaDodSO4/proteinase K, followed by extraction of RNA
with phenol/chloroform (21). HAV RNA was twice ethanol-
precipitated and quantified by cDNA-RNA hybridization
(20). Sequencing of RNA was accomplished by primer
extension in the presence of dideoxynucleotide triphosphates
(L.-H.P., R.W.J., and S.M.L., unpublished data).
RESULTS
Competitive Binding of Neutralizing Monoclonal Antibodies
to HAV. Thirteen available monoclonal antibodies to HAV
neutralized HM175 strain virus when tested individually in a
radioimmunofocus-inhibition assay (Table 1). However, pre-
vious studies have demonstrated that two ofthese antibodies,
K3-4C8 and B5-B3, are directed against spatially distinct
nonoverlapping epitopes on the surface of the virus (8). We
examined the ability ofeach monoclonal antibody to compete
with radiolabeled K3-4C8 or B5-B3 for attachment to HAV
immobilized on a solid-phase support (Fig. 1). These results
suggested that the monoclonal antibodies could be function-
ally grouped into four general categories: antibodies K3-4C8,
K3-2F2, and 813 that strongly compete with K3-4C8 but
enhance the binding of B5-B3 to virus; antibodies 6A5, AG3,
K2-4F2, and 10.09 that strongly compete with K3-4C8 and
weakly compete with B5-B3; antibodies 1B9, 2D2, 3E1, and
AD2 that strongly compete with both K3-4C8 and B5-B3; and
antibodies AE8 and B5-B3 that compete weakly or not at all
with K3-4C8, but strongly compete with B5-B3. Because
antibodies in the first group (antibodies K3-4C8, K3-2F2, and
813) do not competitively inhibit attachment of B5-B3 to
virus, and B5-B3 does not compete for binding with K3-4C8
(Fig. 1), it may be concluded that nonspecific steric hindrance
does not affect the simultaneous attachment of IgG antibod-
ies directed at spatially distinct epitopes on the virus.
However, the enhancement of B5-B3 binding after the
reaction of virus with antibodies K3-4C8, K3-2F2, or 813
suggests that these antibodies induce conformational changes
at the B5-B3 epitope and, therefore, that these epitopes may
be closely situated on the virus capsid. This hypothesis is
further supported by the inhibition ofboth K3-4C8 and B5-B3
binding demonstrated by multiple other antibodies (Fig. 1).
These data thus suggest that the 13 neutralizing monoclonal
antibodies listed in Table 1 are directed against a cluster of
closely spaced epitopes. Furthermore, the neutralization
results shown in Table 1 and previously reported data (8, 22)
suggest that this epitope cluster is highly conserved and
immunodominant in man.
Analysis of HAV-Neutralization-Escape Mutants. The se-
lection of spontaneous HAV-neutralization-escape mutants








FIG. 1. Competition between
monoclonal antibodies for attach-
ment to HAV. Antibody dilutions
were added to virus-coated micro-
titer wells prior to the addition of
much smaller quantities of '25I-
labeled monoclonal antibody K3-
4C8 (hatched bars) or B5-B3 (solid
bars). The quantity of 1251 bound
was compared with that bound in
the absence of any competing
antibody.
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the presence ofantibody that was followed by clonal isolation
from agarose overlays (8). The neutralization resistance of
these mutants was reconfirmed after amplification of virus in
the absence of antibody (Table 2) with some variants (e.g.,
S20), demonstrating partial to complete reversion to neutral-
ization susceptibility. The neutralization resistance of some
HAV mutants has been associated with reduced binding of
the cognate antibody in immunoaffinity hybridization exper-
iments (8). This was confirmed in solid-phase radioimmu-
noassays. Radioiodinated antibodies K2-4F2 and K3-4C8
bound to parent HM175 virus but only K3-4C8 bound to the
two virus mutants, S18 and S30, that had been selected for
resistance to K2-4F2 antibody (data not shown).
To identify capsid protein amino acid mutations associated
with neutralization resistance, and by inference involved in
antibody attachment sites on the virion surface (9, 10), we
partially sequenced RNA extracted from preparations of
purified virus. For purposes of comparison, we sequenced
the complete capsid-encoding regions (P1 domain) of RNA
extracted from mutants S30 and S32 and compared these
RNA sequences with sequence we had obtained from cDNA
clones of parental virus with a normal neutralization pheno-
type (21). S30 was selected for resistance to antibody K2-4F2,
and the titer of S30 was not decreased when incubated with
this antibody, whereas S32 was selected against B5-B3 and
demonstrated partial resistance against this antibody (Table
2).
The only mutation identified in the capsid-encoding region
of S30 virus was a G -* C substitution at base 1677, which
predicted a change from aspartic acid to histidine at residue
70 of capsid protein VP3 (residue 3070). [We have adopted
the nucleotide numbering system and proposed protein
assignments ofCohen et al. (23). By convention, we describe
the 70th residue of capsid polypeptide VP3 as residue 3070.]
Limited RNA sequencing demonstrated that this substitution
was also present in four other mutants selected against
K2-4F2 (S18, S23, S27, and S28), but absent in mutant S20,
which had reverted to neutralization susceptibility during
virus amplification (Table 2). Because of the method of
mutant selection (8), these viruses may represent sibling
variants originally derived from a single neutralization-
resistant parent. However, substitution at this same residue
was also found in an independently selected, K2-4F2-
resistant mutant (43c12), in which an A -- C substitution at
base 1678 predicted replacement of 3070 with alanine. This
variant, which was derived from a rapidly replicating cyto-
pathic HM175 virus substrain (24), has been partially se-
quenced in the P1 region. It also has an A -* G substitution
at base 2797 that predicts replacement of asparagine-1197
with serine. Residue 3070 was unchanged in S32 virus (Table
2). The only mutation within the P1 region of this virus was
a C -> U mutation at base position 2512, predicting a change
from serine to leucine at residue 1102.
Table 2. Neutralization-resistant HAV variants
Control Residue
Antibody Mutant Neut. index neut. index 3070 1102
K24F2 S18 -0.12 1.43 + 0.31 His Ser
S20 0.88 Asp Ser
S23 0.03 His Ser
S27 -0.06 His Ser
S28 0.02 His Ser
S30 -0.09 His Ser
43c12 0.00 Ala Ser
B5-B3 S32 0.63 ± 0.02 0.90 ± 0.12 Asp Leu
Neutralization (neut.) index = loglo reduction in virus titer after
neutralization with the cognate antibody. Control neutralization
index is the neutralization index of parent HM175 virus with same
antibody.
Table 3. Resistance of virus mutants to monoclonal antibodies
S30 S32
Neut. Control Neut. Control
Antibody index neut. index index neut. index
K34C8 0.25 1.10 0.80 0.93
K3-2F2 -0.14 0.82
813 -0.09 0.91 0.58 0.73
6A5 -0.03 1.50 1.15 1.73
AG3 1.41 1.13 1.50 1.13
K24F2 -0.08 1.33 1.05 1.25
10.09 0.19 1.33 0.60 1.00
1B9 0.31 0.80 0.63 0.89
2D2 0.13 1.80 0.89 2.20
3E1 -0.16 1.10 0.50 1.25
AD2 0.21 0.60
AE8 1.84 1.81
B5-B3 0.60 0.92 0.65 1.06
pcAb 0.85 1.21
Neutralization index and control neutralization index are as
defined in Table 2. pcAb, human polyclonal antibody; neut., neu-
tralization.
Immunodominance of the Antigenic Site Containing Residue
3070. We tested S30 virus for resistance to other monoclonal
antibodies (Table 3). Neutralization resistance was evident
with antibodies with activities similar to the cognate antibody
K2-4F2 in competition studies (antibodies 6A5 and 10.09) and
also antibody 1B9 (Fig. 1); however, S30 was at least partially
resistant to antibodies K3-4C8, K3-2F2, 813, 2D2, 3E1, and
B5-B3. The cross-resistance of S30 to other monoclonal
antibodies suggests that the epitopes recognized by these
antibodies comprise a single functional antigenic domain.
Antibodies AE8 and AG3 were notable exceptions in that
they retained neutralizing activity against S30 and thus might
be directed against an antigenic site distinct from that
recognized by the other monoclonal antibodies. We also
assessed the neutralization resistance of the VP1 mutant S32
to monoclonal antibodies other than the cognate B5-B3. This
mutant was partially resistant to neutralization by antibodies
10.09, 2D2, 3E1, and possibly 6A5, but remained susceptible
to K3-4C8, 813, K2-4F2, and 1B9 (Table 3). Complete
resistance was not seen to any antibody.
To determine whether resistance of S30 to multiple anti-
bodies was related to loss ofantibody binding, we determined
the extent of binding of each monoclonal antibody to S30 in
an indirect solid-phase radioimmunoassay (Fig. 2). These
results indicated that neutralization resistance against anti-
bodies K3-2F2, 813, 6A5, K2-4F2, 10.09, and 1B9 was
associated with substantial loss of binding. However, K3-
4C8, 3E1, AD2, AE8, and B5-B3 still effectively recognized
the mutant virus (Fig. 2), even though the ability of several
of these antibodies to neutralize S30 infectivity was substan-
tially reduced (Table 3). None of the monoclonal antibodies,
including the cognate B5-B3, showed reduced binding to S32
(data not shown).
DISCUSSION
The data reported here confirm and extend previous obser-
vations suggesting the existence of an immunodominant
neutralization domain on the HAV capsid. Solid-phase com-
petition studies indirectly suggest that the epitopes recog-
nized by the 13 neutralizing monoclonal antibodies listed in
Table 1 are closely clustered on the virion surface (Fig. 1). A
combination of two of these monoclonal antibodies (K3-4C8
and B5-B3) competes effectively with polyclonal human
postconvalescent antibody for attachment to the virus (8),
suggesting that the immunodominance of the epitopes rec-
Medical Sciences: Ping et al.
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FIG. 2. Binding of neutralizing
monoclonal antibodies to mutant
S30 assessed by an indirect radio-
immunoassay. Antibody binding
to S30 is expressed as the percent-
age of antibody binding to equiv-
alent amounts of parent HM175
virus in companion assays.
ognized by murine antibodies also extends to man. S30, a
neutralization-escape mutant selected for resistance to anti-
body K2-4F2, is at least partially resistant to most other
monoclonal antibodies (Table 3), providing further evidence
for the immunodominance of this antigenic site. We now have
partially localized this antigenic site by demonstrating the
involvement of VP3. Aspartic acid-3070 contributes to this
conformational antigen, as its replacement with histidine was
the only mutation present in the capsid proteins of mutant
S30.
This result was surprising, as previous studies have sug-
gested a primary role for capsid protein VP1 in HAV
antigenicity. Surface labeling studies with intact virus indi-
cate that VP1 is the dominant surface protein of HAV (7).
Furthermore, when Fab fragments from monoclonal antibod-
ies 6A5 and 2D2 bound to and then were cross-linked to intact
virus, subsequent separation of the capsid proteins by elec-
trophoresis in denaturing gels suggested that these antibodies
were predominantly associated with VP1 (15). Nonetheless,
VP3
the participation of VP3 residues in the neutralization epi-
topes recognized by these same monoclonal antibodies (Fig.
2) is not completely unexpected, as in both poliovirus type 3
(PV3) and HRV14 there are conformationally dependent
immunogenic neutralization sites that are formed by residues
contributed by both VP3 and VP1 (10, 11). In addition,
immunization of rats with either purified VP1 or VP3 from
HAV has been shown to induce low levels of antibody
capable of immunoprecipitating and neutralizing virus (25).
While sequence analysis of cloned genomic cDNA sug-
gests that HAV shares a common genomic organization with
other picornaviruses, there is very little homology between
HAV and other picornaviruses at either the nucleotide or
amino acid level. Indeed, a detailed comparison of known
HAV genomic sequences with those of all other picornavi-
ruses indicates that HAVs as a group are only distantly
related to and are uniquely distant from any of the other
picornaviruses (26). Nonetheless, it has been possible to align
the capsid protein amino acid sequences of HAV with those
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FIG. 3. (Upper) Amino acid residues recognized to contribute to neutralization immunogenic sites involving VP3 of HM175 strain HAV,
Sabin strain PV1 (sites 3b and 4), and HRV14 (site NIm-III) (see text). The boxed residues are sites of mutation in escape mutants (with the
exception of leucine-3072 of PV1, where no mutation has yet been identified). Sequences are aligned as described by Palmenberg (26), with HAV
residues numbered at the top. (Lower) Similar alignments of partial amino acid sequences of VP1 from HM175 virus, Sabin PV3, and HRV14.
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of other picornaviruses, based on a sophisticated search for
similarities in the amino acid sequences (26). These align-
ments suggest that residue 3070 is part ofan immunogenic site
that is analogous to neutralization immunogenic sites known
to involve VP3 ofPV1 and PV3 [sites 3b or 4, terminology of
Minor et al. (11, 11)] (9, 11, 27) and HRV14 (site NIm-III) (10)
(Fig. 3). Thus there appears to be substantial conservation of
function as well as structure among these very distantly
related viruses. These VP3 sites are discontinuous (confor-
mational) structures in PV3 and HRV14, involving residues
within VP3 and near the C terminus of VP1. The site
identified in VP3 of HAV may involve analogous VP1
residues, which would explain the results of previous cross-
linking studies with antibodies 6A5 and 2D2 (15).
Residue 1102 also aligns with recognized immunogenic
sites in HRV14 and PV3 (10, 11) (Fig. 3) and is the only site
of mutation in the capsid proteins of mutant S32. However,
the finding that mutations at residues 1102 and 3070 are
functionally related is confusing. At least partial resistance to
antibodies B5-B3, 3E1, 2D2, 10.09, and possibly 6A5 is
conferred by mutations at either residue 1102 or residue 3070
(Table 3). The analogous residues are distant from each other
in the three-dimensional structures of poliovirus and HRV14
and contribute to functionally independent antigenic sites (9-
11, 26). In contrast, the present data suggest that these
residues are relatively closely positioned on the HAV capsid.
A less likely alternative is that neutralization resistance might
be caused by capsid mutations occurring at a distance from
the primary antibody binding site.
Although the neutralization resistance of mutant S30,
selected for resistance to K2-4F2, extended to most of the
other monoclonal antibodies, many of these antibodies con-
tinued to bind to the mutant virus despite lack of efficient
neutralization (compare Table 3 and Fig. 2). This may reflect
a requirement for bivalent binding of many monoclonal
antibodies for neutralization to occur, as demonstrated with
poliovirus (28). Relatively minor perturbations in the confor-
mation of epitopes could continue to permit monovalent
binding of antibody, but lead to unfavorable binding energies
with respect to bivalent attachment and associated changes in
the capsid conformation that might be required for neutral-
ization.
We conclude from these studies that residue 3070 contrib-
utes to the immunodominant HAV antigenic site recognized
by most available monoclonal antibodies. Recognition of the
involvement of VP3 is important for the development of a
HAV vaccine. Additional mapping of capsid protein amino
acid residues contributing to this site may assist in the
development of vaccine immunogens by various biotechno-
logical approaches.
Note Added in Proof. Since submission of this article, we have
completed sequencing the P1 region of 43c12 virus. One additional
mutation was found: methionine to valine at residue 1276.
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